natgillin/translations-raw huggingface dataset:
Pull e) Hold syringe upright and advance plunger rod slowly to expel the air.
Povlecite e) Injekcijsko brizgo držite pokonci in počasi pritiskajte na potiskalo bata, da iztisnete zrak.
Shake the vial vigorously for at least 30 seconds until the suspension appears uniform.
Vialo močno stresajte vsaj 30 sekund, dokler suspenzija ni homogena.
The incidence of weight gain of ≥ 7 % from baseline to last visit (week 12) was 21.5 % for Abilify Maintena compared with the placebo group 8.5 %.
Pojavnost povečanja telesne mase za ≥ 7 % od izhodišča do zadnjega obiska (12. teden) je znašala 21,5 % za zdravilo Abilify Maintena v primerjavi z 8,5 % za placebo.
Step 3: Preparation prior to injection a) Remove the cover, but not the adapter from the package.
Korak 3: Priprava pred injiciranjem a) S škatle odstranimo pokrov, nastavek pa pustimo v škatli.
Thus, superiority of Abilify Maintena over the aripiprazole Long-Acting Injectable 50 mg/25 mg was established and the validity of the trial design was confirmed.
Posledično je bila ugotovljena superiornost zdravila Abilify Maintena v primerjavi z dolgodelujočim parantertalnim aripiprazolom 50 mg/25 mg in s tem potrjena veljavnost načrta preskušanja.
Gluteal injections should be alternated between the two gluteal muscles.
Injiciranje v glutealno mišico je treba izmenjevati med obema glutealnima mišicama.
Care must be taken to avoid inadvertent injection into the blood vessel.
Potrebna je previdnost, da ne pride do nenamernega injiciranja v krvno žilo.
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis)
(vključno s pljučno embolijo in globoko vensko trombozo)
• grinding of teeth or clenching of the jaw
• škrtanje z zobmi ali stiskanje čeljusti,
• low level of a specific type of white blood cells (neutropenia), low haemoglobin or red blood cell count, low level of blood platelets
• nizka raven specifičnih belih krvničk (nevtropenija), nizka raven hemoglobina ali nizka raven rdečih krvničk, nizka raven trombocitov,
You should not be given Abilify Maintena if you are pregnant unless you have discussed this with your doctor.
Če ste noseči, vam ne smejo dajati zdravila Abilify Maintena, razen če ste se tako dogovorili z zdravnikom.
Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.
Učinek zdravil iz te skupine (»Class Effect«): v prvih nekaj dneh zdravljenja se lahko pri dovzetnih posameznikih pojavijo simptomi distonije, podaljšanega nenormalnega krčenja mišičnih skupin.
Abilify Maintena should not be used to manage acutely agitated or severely psychotic states when immediate symptom control is warranted.
Zdravila Abilify Maintena ne smemo uporabljati, kadar je potreben takojšen nadzor simptomov pri akutno agitiranih ali zelo psihotičnih bolnikih.
Close supervision of high risk patients should accompany antipsychotic treatment.
Med antipsihotičnim zdravljenjem je treba bolnike z visokim tveganjem skrbno nadzirati.
Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with aripiprazole.
V nekaterih primerih je bila hiperglikemija zelo izrazita in povezana s ketoacidozo ali hiperosmolarno komo ali smrtjo.
If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered.
Če so s 400 mg odmerkom povezane neželene reakcije, je treba razmisliti o zmanjšanju odmerka na
i) Do not store the reconstituted suspension in the syringe.
i) Rekonstituirane suspenzije ne shranjujte v injekcijski brizgi.
• enlargement of breast in men, breast tenderness, vaginal dryness
• povečanje prsi pri moških, občutljivost dojk, suhost nožnice,
In a short-term (12-week), randomised, double-blind, placebo-controlled trial with Abilify Maintena 400 mg/300 mg treated subjects the symptoms which had at least twice the incidence of placebo were increased weight and akathisia.
(12-tedenskem), randomiziranem, dvojno slepem, s placebom nadzorovanem preskušanju so pri preiskovancih, zdravljenih z zdravilom Abilify Maintena 400 mg/300 mg, opazili simptoma povečane telesne mase in akatizije, za katera je bila značilna vsaj dvakrat večja pojavnost v primerjavi s placebom.
b) Using the syringe with pre-attached needle, withdraw the pre-determined solvent volume from the vial of the solvent into the syringe.
b) Z injekcijsko brizgo s predhodno pritrjeno iglo izvlecite predhodno določeno količino vehikla iz viale v injekcijsko brizgo.
In clinical trials of treatment with oral aripiprazole, the incidence of QT prolongation was comparable to placebo.
V kliničnih preskušanjih peroralnega aripiprazola je bila pojavnost podaljšanja intervala QT
Add 1.5 ml solvent to reconstitute the powder.
Dodajte 1,5 ml vehikla, da rekonstituirate prašek.
Remember to rotate sites of injections between the two gluteal or deltoid muscles.
Ne pozabite izmenjavati mesta injiciranja med obema glutealnima ali deltoidnima mišicama.
Similarly, there was no clinically relevant effect of gender in a population pharmacokinetic analysis of Abilify Maintena in clinical trials in patients with schizophrenia.
Prav tako med spoloma ni bilo opaznih razlik v populacijski farmakokinetični analizi zdravila Abilify Maintena v kliničnih preskušanjih pri shizofrenih bolnikih.
If you see more than one doctor, be sure to tell them that you are receiving Abilify Maintena.
Če obiskujete več zdravnikov, jih morate seznaniti s tem, da prejemate zdravilo Abilify
• jerky resistance to passive movement as muscles tense and relax, abnormally increased muscle tone, slow body movement
• sunkovit upor pri pasivnih gibih, ko se mišice napenjajo in sproščajo, nenormalno povečanje napetosti mišic, počasno gibanje telesa,
• increased levels of insulin, a hormone regulating blood sugar levels
• povišana raven hormona inzulina, ki uravnava sladkor v krvi,
After oral administration of aripiprazole, there are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects.
Po oralnem odmerku aripiprazola se farmakokinetika aripiprazola med zdravimi starejšimi in mlajšimi odraslimi preiskovanci ne razlikuje.
This trial consisted of a screening phase and 4 treatment phases: Conversion, Oral Stabilisation, Abilify Maintena Stabilisation, and Double-blind Placebo-controlled.
To preskušanje so sestavljale presejalna faza in štiri faze zdravljenja: faza prehoda, faza peroralne stabilizacije, faza stabilizacije z zdravilom Abilify Maintena in dvojno slepa s placebom nadzorovana faza.
• swelling of hands, ankles or feet
• zatekanje rok, gležnjev ali stopal,
Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
Zdravilo Abilify Maintena je indicirano za vzdrževalno zdravljenje shizofrenije pri odraslih bolnikih, stabiliziranih s peroralnim aripiprazolom.
Dose adjustments due to interactions with CYP2D6 and/or CYP3A4 inhibitors and/or CYP3A4 inducers
Prilagajanje odmerka zaradi medsebojnega delovanja z zaviralci CYP2D6 in/ali CYP3A4 in/ali induktorji CYP3A4
The reconstituted suspension should be used immediately but may be stored below 25°C for up to 4 hours in the vial.
Rekonstituirano suspenzijo je treba uporabiti takoj po rekonstituciji, vendar jo lahko za največ 4 ure shranite v viali pri temperaturi nižji od 25 °C.
• changes in your level of alertness, drowsiness
• spremembe stanja zavesti, zaspanost,
It is important that you carry on receiving Abilify Maintena for as long as your doctor has told you to.
Abilify Maintena nadaljujete tako dolgo, kot vam je svetoval zdravnik.
The SmPC for Abilify Maintena prolonged-release suspension for injection lists oculogyric crisis in section 4.8 and the PIL lists fixation of eye balls in one position as an uncommon side effect.
Povzetek glavnih značilnosti zdravila Abilify Maintena suspenzija za injiciranje s podaljšanim sproščanjem okulogirno krizo navaja v poglavju 4.8, Navodilo za uporabo pa navaja fiksiranje očesnih zrkel kot občasni neželeni učinek.
• accidental inhalation of food with risk of pneumonia (lung infection)
• krči mišic v grlu, • naključno vdihanje hrane s tveganjem za pljučnico (okužba pljuč),
Aripiprazole oral doses ranging from 0.5 to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of 11C-raclopride, a D2/D3 receptor ligand, to the caudate and putamen detected by positron emission tomography.
S pozitronsko emisijsko tomografijo so pokazali, da je 2-tedenska uporaba odmerkov od 0,5 do 30 mg peroralnega aripiprazola enkrat na dan pri zdravih preiskovancih povzročila od odmerka odvisno zmanjšanje vezave 11C-rakloprida, liganda receptorjev D2/D3, v nucleusu caudatusu in putamnu.
Abilify Maintena is intended for adult patients with schizophrenia who are sufficiently stabilised during treatment with oral aripiprazole.
Zdravilo Abilify Maintena je namenjeno odraslim bolnikom s shizofrenijo, ki so bili med zdravljenjem s peroralno obliko aripiprazola ustrezno stabilizirani.
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection EU/1/13/882/001
Abilify Maintena 300 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem EU/1/13/882/001
Body type
Telesna masa
Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4.
Na podlagi raziskav in vitro dehidrogenacijo in hidroksilacijo aripiprazola povzročajo encimi CYP3A4 in CYP2D6, N-dealkilacijo pa katalizira CYP3A4.
20 seconds c) Visually inspect the syringe for particulate matter and discoloration prior to administration.
20 sekund c) Rekonstituirano suspenzijo pred dajanjem preglejte za delci in obarvanjem.
• sensitivity to light
• izpuščaj, • občutljivost kože za svetlobo,
• a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness since this may be a sign of a condition called neuroleptic malignant syndrome (NMS).
• kombinacijo zvišane telesne temperature, hitrega dihanja, znojenja, togosti mišic, zmanjšane stopnje zavesti ali zaspanosti, saj je to lahko znak stanja, ki se imenuje maligni nevroleptični sindrom (MNS);
Patients eligible for the Double-blind, Placebo-controlled Phase were randomly assigned in a 2:1 ratio to double-blind treatment with Abilify Maintena or placebo, respectively.
Bolniki, ki so bili primerni za vključitev v dvojno slepo s placebom nadzorovano fazo, so bili v razmerju 2 : 1 randozimirano porazdeljeni v skupino, ki je prejemala dvojno slepo zdravljenje z zdravilom Abilify Maintena, ali skupino, ki je prejemala dvojno slepo zdravljenje s placebom.
In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg (41 times highest recommended daily aripiprazole dose) with no fatalities.
V kliničnih preskušanjih in iz izkušenj v obdobju trženja so ugotovili naključno ali namerno akutno preveliko odmerjanje aripiprazola samega pri odraslih bolnikih z ocenjenimi odmerki do 1.260 mg
• anticonvulsants used to treat epilepsy (such as carbamazepine, phenytoin, phenobarbital)
• antikonvulzivi, ki se uporabljajo za zdravljenje epilepsije (kot so karbamazepin, fenitoin, fenobarbital),
Clear glass pre-filled syringe (type-I glass) with grey chlorobutyl stoppers (front-, middle- and end stopper), polypropylene front assembly, polypropylene finger grip, plunger rod, and silicone over-cap.
Napolnjena injekcijska brizga iz prozornega stekla (steklo tipa I) s sivimi klorobutilnimi zamaški (sprednji, srednji in končni zamašek), polipropilenskim sprednjim sklopom, polipropilenskim oprijemom, potiskalom bata in silikonskim pokrovčkom.
• muscle problems
• težave z mišicami,
Shelf-life after reconstitution: 4 hours below 25 °C Do not store the reconstituted suspension in the syringe.
Rok uporabnosti po rekonstituciji: 4 ure pri temperaturi do 25 °C Rekonstituirane suspenzije ne shranjujte v injekcijski brizgi.
No dosage adjustment is required for patients with mild or moderate hepatic impairment.
Pri bolnikih z blago ali zmerno okvaro jeter odmerka ni treba prilagajati.
Your doctor will give it to you as a single injection into the gluteal or deltoid muscle (buttock or shoulder) every month.
Zdravnik vam bo zdravilo vsak mesec dal v obliki ene injekcijo v glutealno ali deltoidno mišico
• prolonged and/or painful erection
• simptomi odtegnitve zdravila pri novorojenčku, • dolgotrajna in/ali boleča erekcija,
If it's not possible to advance plunger rod to expel the air, check that plunger rod is rotated to a complete stop.
Če potiskala bata ni več mogoče potisniti naprej in iztisniti zraka, se prepričajte, ali potiskala bata ni mogoče več obračati.
Therefore, Abilify Maintena is non-inferior to aripiprazole oral tablets 10-30 mg.
Zato je zdravilo Abilify Maintena neinferiorno zdravilu aripiprazol v 10-30 mg peroralnih tabletah.
Parkinsonism events followed in frequency of 6.9 % for Abilify Maintena, 4.15 % for oral aripiprazole 10-30 mg tablets and 3.0 % for placebo, respectively.
Sledili so dogodki parkinsonizma, in sicer z naslednjo pogostnostjo: 6,9 % pri zdravilu Abilify Maintena, 4,15 % pri aripiprazolu v 10-30 mg peroralnih tabletah in 3,0 % pri placebu.
In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively.
V kliničnem preskušanju peroralnega aripiprazola pri zdravih preiskovancih je močan zaviralec CYP3A4 (ketokonazol) zvečal AUC aripiprazola za 63 %, njegov Cmax pa za 37 %.
The incidences of Abilify Maintena patients with prolactin levels > 1 time the upper limit of normal range (ULN) was 1.9 % compared to 7.1 % for placebo patients.
Pojavnost bolnikov, zdravljenih z zdravilom Abilify Maintena in ravnmi prolaktina z > 1-kratno zgornjo mejo normalnih vrednosti (ULN), je znašala 1,9 % v primerjavi s 7,1 % bolnikov, ki so prejemali placebo.
Abilify Maintena 400 mg Vial
Abilify Maintena 400 mg viala
*If there's resistance or difficulty expelling air, check that plunger rod is rotated to a complete stop.
*Če začutite upor ali imate pri iztisu zraka težave, se prepričajte, da potiskala bata ni mogoče več obračati.
* 200 mg and 160 mg can be achieved via adjustment of the injection volume only by using Abilify Maintena powder and solvent for prolonged-release suspension for injection.
* Prilagoditev odmerka na 200 mg in 160 mg je mogoča samo z uporabo zdravila Abilify Maintena prašek in vehikel za suspenzijo za injiciranje s podaljašnim sproščanjem.
The incidence of Abilify Maintena patients with prolactin levels > 1 time the upper limit of normal range (ULN) at any assessment was 5.4 % compared with 3.5 % of the patients on oral aripiprazole tablets 10-30 mg.
Pojavnost bolnikov, zdravljenih z zdravilom Abilify Maintena in ravnmi prolaktina z > 1-kratno zgornjo mejo normalnih vrednosti (ULN), je po vseh ocenah znašala 5,4 %, v primerjavi s 3,5 % pri bolnikih, ki so prejemali aripiprazol v 10-30 mg peroralnih tabletah.
Male patients generally had a higher incidence than female patients in each treatment group.
V posamezni preiskovani skupini je bila pojavnost v splošnem višja pri bolnikih kot pri bolnicah.
Quinidine and other strong CYP2D6 inhibitors
Kinidin in drugi močni zaviralci CYP2D6
Non-clinical safety data for orally administered aripiprazole reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.
Predklinični podatki za peroralno odmerjen aripiprazol na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja in razvoja niso pokazali posebnega tveganja za človeka.
Excess amount of gastric juice flowing back (refluxes) into the esophagus (gullet or the tube that goes from mouth to stomach through which food passes),
Prekomerna količina želodčnega soka (refluksi) v požiralniku (požiralnik ali cev, ki gre iz ust v želodec, skozi katero potuje hrana), ki povzroča zgago in lahko poškoduje požiralnik.
Step 3: Injection procedure a) Twist and pull off Over-cap and Tip-cap.
Korak 3: Postopek injiciranja a) Obrnite in snemite zunanji pokrov ter pokrovček konice.
Abilify Maintena 300 mg Vial
Abilify Maintena 300 mg viala
Overall, 1.3 % of oral aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials.
V celoti so v teh preskušanjih cerebrovaskularne neželene učinke zabeležili pri 1,3 % bolnikov, zdravljenih s peroralnim aripiprazolom, in pri 0,6 % bolnikov, ki so dobivali placebo.
By the 7th day, the median aripiprazole concentrations further decline to concentrations following an IM depot dose with no dose dumping.
Do 7. dne naj bi mediana koncentracij aripiprazola še naprej upadala do koncentracij po i.m.
In an open label study comparing bioavailability of Abilify Maintena administered in the deltoid or gluteal muscle, injection site related reactions were slightly more frequent in the deltoid muscle.
V odprti študiji, ki je primerjala biorazpoložljivost zdravila Abilify Maintena, injeciranega v deltoidno oziroma glutealno mišico, je bila pojavnost reakcij na mestu aplikacije pri deltoidni mešici za spoznanje večja.
A single-dose study with oral administration of aripiprazole to subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.
Jetrna okvara Študija z enim samim odmerkom oralnega aripiprazola pri preiskovancih z različno stopnjo jetrne ciroze (razredi A, B in C po Child-Pughu) ni pokazala pomembnega vpliva jetrne okvare na farmakokinetiko aripiprazola in dehidroaripiprazola.
Step 2: Reconstitution of the powder a) Push plunger rod slightly to engage threads.
Korak 2: Rekonstitucija praška a) Rahlo pritisnite na potiskalo bata, da navoji zaskočijo.
Indicator line Plunger Rod b) Vertically shake the syringe vigorously for 20 seconds until the reconstituted suspension appears uniform.
Potiskalo bata b) Injekcijsko brizgo 20 sekund navpično močno stresajte, dokler rekonstitucijska suspenzija ni homogena.
Do not store the reconstituted suspension in the syringe.
Rekonstituirane suspenzije ne shranjujte v injekcijski brizgi.
• certain medicines to treat HIV infection (such as efavirenz, nevirapine, and protease inhibitors e.g. indinavir, ritonavir)
• določena zdravila za zdravljenje okužbe s HIV (kot so efavirenz, nevirapin, zaviralci proteaz,
• acne, skin condition of the face where the nose and cheeks are unusually red, eczema, skin hardening
• akne, kožna bolezen na obrazu, za katero so značilni nenavadna pordelost nosu in lic, ekcemi,
The PSUR for the brand leader, Abilify and Abilify Maintena, gathers data from the immediate-realease formulations and the prolonged-release suspension for injection.
Poročilo PSUR o vodilni znamki zdravil Abilify in Abilify Maintena je zbralo podatke za farmacevtske oblike suspenzij za injiciranje s takojšnim sproščanjem in s podaljšanim sproščanjem.
In the Double-blind Placebo-controlled Phase of the 52-week trial, from baseline to last visit there was a mean decrease in prolactin levels in Abilify Maintena (−0.38 ng/ml) compared with a mean increase in placebo (1.67 ng/ml).
V dvojno slepi s placebom nadzorovani fazi 52-tedenskega preskušanja je bilo od izhodiščne vrednosti do zadnjega obiska srednje zmanjšanje vrednosti prolaktina v skupini, ki je prejemala zdravilo Abilify Maintena, (−0,38 ng/ml) v primerjavi s srednjim povišanjem v skupini s placebom (1,67 ng/ml).
Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritus, or urticaria)
anafilaktična reakcija, angioedem, vključno z oteklim jezikom, edem jezika, edem obraza, pruritus ali urtikarija)
And then, rotate plunger rod until the rod stops rotating to release diluent.
Nato obračajte potiskalo bata, dokler se ne preneha obračati, da sprostite redčilo.
In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolisers (see section 4.2).
CYP2D6 lahko sočasna uporaba z močnimi zaviralci CYP3A4 povzroči večjo koncentracijo aripiprazola v plazmi kot pri osebah, ki dobro presnavljajo s CYP2D6.
Vial Type-I glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.
Viala iz stekla tipa I, zaprta z laminirano gumijasto zaporko in zapečatena z aluminijastim pokrovčkom s snemljivo zaporko.
Maintenance treatment of schizophrenia in adults The efficacy of Abilify Maintena in the maintenance treatment of patients with schizophrenia was established in two randomised, double-blind, long-term trials.
Učinkovist zdravila Abilify Maintena pri vzdrževalnem zdravljenju bolnikov s shizofrenijo so ugotavljali v dveh randomiziranih dvojno slepih dolgotrajnih preskušanjih.
• distortion of the senses of taste and smell
• popačenje čutov okusa in vonja, • fiksacija očesnih zrkel,
Acute treatment of schizophrenia in adults
Klinična učinkovitost in varnost Vzdrževalno zdravljenje shizofrenije pri odraslih bolnikih
If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8).
pojavijo znaki in simptomi tardivne diskinezije, je treba razmisliti o zmanjšanju odmerka ali prekinitvi zdravljenja (glejte poglavje 4.8).
• during blood tests your doctor may find higher amounts of creatine phosphokinase in your blood (enzyme important for muscle function)
• med krvnimi preiskavami lahko vaš zdravnik v krvi odkrije večje količine kreatin-fosfokinaze
Sodium dihydrogen phosphate monohydrate Sodium hydroxide
Natrijev dihidrogenfosfat monohidrat Natrijev hidroksid
- higher amounts of alanine aminotransferase
- zvišane količine jetrnih encimov, - zvišane količine alanin aminotransferaze,
Volume to Inject
Količina za injiciranje
• a combination of any of these symptoms: excessive sleepiness, dizziness, confusion, disorientation, difficulty talking, difficulty walking, muscle stiffness or shaking, fever, weakness, irritability, aggression, anxiety, increase in blood pressure, or seizures that can lead to unconsciousness.
dezorientacija, težave pri govoru, težave pri hoji, okorelost mišic ali tresenje, povišana telesna temperatura, šibkost, razdražljivost, agresija, anksioznost, povečan krvni tlak ali krči, ki lahko vodijo v nezavest;
These medicines may increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with Abilify Maintena, you should see your doctor.
Če opazite kakršen koli neobičajen simptom ob jemanju katerega od teh zdravil skupaj z zdravilom Abilify Maintena, obiščite zdravnika.
Dose adjustments of Abilify Maintena in patients who are taking concomitant strong CYP2D6 inhibitors, strong CYP3A4 inhibitors, and/or CYP3A4 inducers for more than 14 days
Prilagoditve odmerka zdravila Abilify Maintena pri bolnikih, ki več kot 14 dni sočasno jemljejo močne zaviralce CYP2D6 ali močne zaviralce CYP3A4 in/ali induktorje CYP3A4
2 ml Type-1 glass vial stoppered with a laminated rubber stopper and sealed with a flip-off aluminium cap.
2 ml viala iz stekla tipa I, zaprta z laminirano gumijasto zaporko in zapečatena z aluminijastim pokrovčkom s snemljivo zaporko.
Twist + Pull Off b) Select one of the following hypodermic safety needles depending on the injection site and patient's weight.
Obrnite + snemite b) Glede na mesto injiciranja in telesno maso bolnika izberite eno od spodnjih varnostnih podkožnih igel.